Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2007-10-02
2007-10-02
Harris, Alana M. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C530S300000, C436S086000, C424S009100, C424S009200, C424S184100, C424S185100, C514S001000, C514S002600, C514S004300
Reexamination Certificate
active
10887588
ABSTRACT:
The present invention provides a mutant oligonucleotide composition encoding a cellular c-Src tyrosine kinase oncogene. Methods for isolating, expressing and characterizing recombinant Src mutant polypeptide are also provided. The invention further relates to methods for utilizing such oligonucleotides, polypeptides, agonists and antagonists for applications, which relate to research, diagnostics, and clinical arts. More specifically, this invention provides methods of diagnosing, treating, immunizing, and creating transgenic animals based on use of such mutant Src.
REFERENCES:
patent: 5336615 (1994-08-01), Bell et al.
patent: WO93/14193 (1993-07-01), None
Stehelin et al. “DNA related to the transforming gene(s) of avian sarcoma viruses is presenting normal avian DNA”Nature, 1976, 260:170-173.
Brugee et al. “Identification of a transformation-specific antigen induced by an avian sarcoma virus”Nature, 1977, 269:346-348.
Jove et al. “Cell transformation by the viral SRC oncogene”Annu. Rev. Cell Dev. Biol., 1987, 3:31-56.
Thomas et al. “Cellular functions regulated by SRC family kinases”Annu. Rev. of Cell Dev. Biol., 1997, 13:513-609.
Hamaguchi et al. “Augmentation of metalloproteinase (gelatinase) activity secreted from Rous sarcoma virus-infected cells correlates with transforming activity ofsrc” Oncogene, 1995, 10:1037-1043.
Egan et al. “Transformation by oncogenes encoding protein kinases induces the metastatic phenotype”Science, 1987, 238:202-205.
Tatsuka et al. “Different metastatic potentials ofras- andsrc- transformed BALB/c 3T3 A31 variant cells”Mol. Carcinogenesis, 1996, 15:300-308.
Rosen et al. “Analysis of pp60c-srcprotein kinase activity in human tumor cell lines and tissues”J. Biol. Chem., 1986, 261:13754-13759.
Bolen et al. “Activation of pp60c-srcprotein kinase activity in human colon carcinoma”Proc. Natl. Acad. Sci. USA, 1987, 84:2251-2255.
Cartwright et al. “pp60c-srcactivation in human colon carcinoma”Amer. Soc. for Clinical Invest., Inc., 1989, 83:2025-2033.
Talamonti et al. “Increase in activity and level of pp60c-srcin progressive stages of human colorectal cancer”J. Clin. Invest., 1991, 91:53-60.
Cartwright et al. “Elevated c-Src tyrosine kinase activity in premalignant epithelia of ulcerative colitis”J. Clin. Invest., 1994, 93:509-515.
Termuhlen et al. “Site-specific differences in pp60c-srcactivity in human colorectal metastases”J. Surg. Res., 1993, 54:293-298.
Mao et al. “Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential”Oncogene, 1997, 15:3083-3090.
Cooper et al. “Tyr527is phosphorylated in pp60c-src: Implications for regulation”Science, 1986, 231:1432-1434.
Cartwright et al. “Cell transformation by pp60c-srcmutated in the carboxy-terminal regulatory domain”Cell, 1987, 49:83-91.
Dmiecik et al. “Activation and suppression of pp60c-srctransforming ability by mutation of its primary sites of tyrosine phosphorylation”Cell, 1987, 49:65-73.
Piwnica-Worms et al. “Tyrosine phosphorylation regulates the biochemical and biological properties of pp60c-src”Cell, 1987, 49:75-82.
Reynolds et al. “Activation of the oncogenic potential of the avian cellularsrcprotein by specific structural alteration of the carboxy terminus”Embo. J., 1987, 6:2359-2364.
Jove et al. “In vivo phosphorylation states and kinase activities of transforming p60c-srcmutants”Oncogene Res., 1989, 5:49-60.
Bjorge et al. “Characterization of two activated mutants of human pp60c-srcthat escape c-Src kinase regulation by instinct mechanisms”J. Biol. Chem., 1995, 270:24222-24228.
Wang et al. “c-src structure in human cancers with elevated pp60c-srcactivity”Bre. J. Cancer, 1991, 64:531-533.
Snyder et al. “Phosphorylation of tyrosine-416 is not required for the transforming properties and kinase activity of pp60c-src”Cell, 1983, 32:891-901.
Tanaka et al. “DNA sequence encoding the amino-terminal region of the human c-srcprotein: Implications of sequence divergence amongsrc-type kinase oncogenes”Mol. Cell Biol., 1987, 7:1978-1983.
Tanaka et al. “Expression of a molecularly cloned human c-srconcogene by using a replication-competent retroviral vector”Mol. Cell Biol., 1986, 6:3900-3909.
Mao et al. “Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential”Oncogene, 1997, 15:3083-3090.
Jove et al. “Enzymatically inactive p60c-srcmutant with altered ATP-binding site is fully phosphorylated in its carboxy-terminal regulatory region”Cell, 1987, 50:937-943.
Nucleic acid database sheet. Data from U.S. Patent No. 5,336,615, 1994.
Amino acid and nucleic acid databases, Sequence 3 from U.S. Appl. No. 07/820,011, now U.S. Patent 5,336,615.
Nucleic acid database sheet, Accession No. AAQ46688, WO 93/14193A, Yale University, Jul. 22, 1993.
Nucleic acid/amino acid database sheet: Accession No. AAR39706, WO 93/14193A, Yale University, Jul. 22, 1993.
Nucleic acid database sheet, Sequence 3, U.S. Patent No. 5,336,615, Aug. 9, 1994.
Nucleic acid/amino acid database sheet, Sequence 4, U.S. Patent No. 5,336,615, Aug. 9, 1994.
Taurog et al. “HLA-B27 in inbred and non-inbred transgenic mice”J. Immunology, 1988, 141:4020-4023.
Houdebine “Production of pharmaceutical proteins from transgenic animals”J. Biotechnology1994, 34:269-287.
Mullins and Mullins “Perspectives series: Molecular medicine in genetically engineered animals”J. Clin. Invest., 1996, 98(11)supplement:S37-S40.
Mullins et al. “Expression of the DBA/2J Ren-2 gene in the adrenal gland of transgenic mice”EMBO J., 1989, 8(13):4065-4072.
Mullins et al. “Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene”Nature, 1990, 344:541-544.
Hammer et al. “Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human B2m: an animal model of HLA-B27-associated human disorders”Cell, 1990, 63:1099-1112.
Mullins and Mullins “Transgenesis in nonmurine species”Hypertension, 1993, 22:630-633.
Overbeek, P.S. Transgenic Animal Technology, A laboratory handbook, Pinkert, C.A. Ed., Academic Press, 1stEdition, Jan. 15, 1994, pp. 96-98.
Wall, R.J. “Transgenic livestock: progress and prospects for the future”Theriogenology, 1996, 45:57-68.
Kappel et al “Regulating gene expression in transgenic animals”Curr. Opinion Biotech., 1992, 3:548-553.
Stratagene 1997/1998 catalog, p. 118 and accompanying instruction manual.
Irby Rosalyn B.
Yeatman Timothy J.
Harris Alana M.
Saliwanchik Lloyd & Saliwanchik
University of South Florida
LandOfFree
Mutated Src oncogene composition and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mutated Src oncogene composition and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mutated Src oncogene composition and methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3835892